Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

BACKGROUND: Following the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate data from clinical trials to clinical practice,...

Descripción completa

Detalles Bibliográficos
Autores principales: Attili, Ilaria, Valenza, Carmine, Santoro, Celeste, Antonarelli, Gabriele, Trillo Aliaga, Pamela, Del Signore, Ester, Catania, Chiara, Spitaleri, Gianluca, Passaro, Antonio, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399686/
https://www.ncbi.nlm.nih.gov/pubmed/36033444
http://dx.doi.org/10.3389/fonc.2022.980765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399686/
https://www.ncbi.nlm.nih.gov/pubmed/36033444
http://dx.doi.org/10.3389/fonc.2022.980765

Ejemplares similares